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Introduction: It has long been established that the Human Immunodeficiency Virus (HIV) 
and its effects, such as its impact on the immune system and then the numerous 
consequences on other biological systems including the central nervous system (CNS), 
have had a significant effect worldwide. This is particularly relevant in South Africa, where 
the prevalence of adults living with HIV remains high. However, with the improved access 
to antiretroviral therapy (ART), more children are now being born uninfected with HIV 
while still being exposed to the virus in utero. Exposure to HIV in utero may still 
negatively affect the developing brain of these children. However, the biological 
mechanisms involved in the neurodevelopmental outcomes in HIV-exposed uninfected 
(HEU) children are still largely unknown. Evidence from clinical studies showed that HEU 
children have an altered immune regulation compared to their unexposed counterparts, 
and this is hypothesised to play a role in neurodevelopmental outcomes in HEU children. 
The aim of this study was to evaluate the longitudinal relationship between the 
inflammatory environment of pregnant mothers living with HIV on ART and their children 
and the association of the inflammatory environment with neurodevelopmental outcomes 
in HEU children. 
 
Methods: This study was performed in a sub-sample of the Drakenstein Child Health 
Study (DCHS), a South African birth cohort of 1137 mother-infant pairs. This sub-study 
included mothers at ≈26 weeks gestation (n=267), their infants at 6-10 weeks (n=222) and 
children at 24-28 months (n=267). Maternal HIV status was determined at ≈26 weeks 
gestation. This sub-study included n=190 HIV negative mother-infant pairs and n=77 HIV 
positive mother-infant pairs. Serum inflammatory markers (Granulocyte-macrophage 
colony-stimulating factor (GM CSF), Interferon-γ (IFN-γ), Interleukin IL-1β, IL-2, IL-4, IL-5, 
IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, tumour necrosis factor-α (TNF-α), neutrophil 
gelatinase-associated lipocalin (NGAL/Lcn2) and metalloproteinase-9 (MMP-9)) were 
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analyzed in all study participants with a multiplex bead array and ELISA. The Bayley Scales 
of Infant and Toddler Development (Bayley-III) were used to assess the 
neurodevelopmental domains: cognitive, motor, language, social-emotional behaviour 
and adaptive behaviour at 24-28 months of age. 
 
Results: Mothers living with HIV on ART had significantly lower levels of the inflammatory 
markers GM-CSF and MMP9 compared to mothers without HIV. Serum levels of 
inflammatory markers IFN-γ and IL-1β were significantly lower in HEU infants at 6-10 
weeks compared to HIV-unexposed uninfected (HUU) infants. At 24-28 months of age, 
HEU children also proved to have significantly lower serum levels of the inflammatory 
markers IFN-γ, IL-1β, IL-2 and IL-4 compared with HUU children. Increased levels of the 
inflammatory markers; GM-CSF, IFN-γ, IL-10, IL-12p70, IL-1β, IL-2, IL-4, IL-6 and Lcn2 in 
HEU infants at 6-10 weeks of age was associated with impaired motor neurodevelopment 
at 24-28 months of age.  
 
Conclusion: This is the first study to evaluate the longitudinal associations of immune 
markers with neurodevelopment in HEU children. The results show that maternal HIV 
infection was associated with lower levels of inflammatory markers in mothers and their 
children. Our results further indicate that an altered immune system in HEU infants, 
specifically at the earliest stages of life, was associated with impaired motor function at 2 
years of age. These findings may provide further insights into the involvement of immune 
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It has long been established that the Human Immunodeficiency Virus (HIV) and its effects, 
such as its impact on the immune system and the numerous consequences on other 
biological systems including the central nervous system (CNS), have had a significant 
impact worldwide. This is relevant particularly in South Africa, where the prevalence rate 
of adults living with HIV is still at 18.9% (1). Globally South Africa has the biggest and 
most high-profile HIV epidemic, with an estimated 7.2 million people living with HIV in 
2017 (1). However, with the increased use of antiretroviral therapy (ART) more children are 
now born uninfected with HIV but still being exposed in utero to the virus. In 2018, 
UNAIDS reported that 4.4 million people were receiving treatment in South Africa; this is 
more than half (61%) of individuals infected with HIV (2). HIV infection amongst South 
African children between the ages of 0 and 4 has declined from 26,000 in 2010 to 13,000 
in 2017 (1). This is primarily due to prevention of mother to child transmission (PMTCT) 
programs; where the rate of transmission is 1.3% in 2017, which is down from 3.6% in 
2011 (3), as well as the fact that there is an estimated 53 000 children in South Africa who 
have averted infection with HIV due to PMTCT, compared to only 18 000 children in 2007 
(2). With the decline in children living with HIV there is now a drastic increase in the 
number of children between the ages of 0 and 14 who are exposed but uninfected with 
HIV. However, exposure in utero may still negatively affect the health of these children. 
Numerous studies have so far been conducted to evaluate the effect of HIV exposure in 
utero on these children including assessing their neurodevelopmental outcome (4). 
Unfortunately, the biological mechanisms involved in the neurodevelopmental outcomes 
in HIV-exposed uninfected (HEU) children are still largely unknown.  
 
Recently the role of the immune system in neurodevelopment and neuropsychiatric 
disorders has become a growing focus in scientific research. An increasing number of 
studies suggest that maternal immune activation (MIA) and increased levels of certain 
inflammatory markers during pregnancy can contribute to impaired brain development of 
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the foetus (5–11). Moreover, studies have shown that increased levels of inflammatory 
cytokines, such as Interleukin-6 (IL-6), IL-1β and Tumour necrosis factor-α (TNF-α) are 
associated with numerous neuropsychiatric disorders, such as schizophrenia and autism 
spectrum disorder (12–15). It is well known that HIV has a significant impact on the 
immune system. Therefore, the relationship between this infamous disease and its 
potential effect on neurodevelopment via the immune system is a crucial area of 
investigation. 
 
HIV has a significant impact on the immune system of the mother during pregnancy; this 
in turn may impact the development of the foetus. According to studies previously 
conducted, HIV impacts the immune system by creating a pro-inflammatory environment 
(16,17), which is characterised predominantly by increased levels of certain cytokines, 
such as IL-1, IL-6 and TNF-α, and other inflammatory markers, such as metalloproteinase 9 
(MMP9) and lipocalin 2 (Lcn2). Peripheral immune activation during pregnancy is a normal 
occurrence at certain stages of the pregnancy such as in the first and third trimester 
(18,19). However, with HIV infection inflammatory markers are increased even further (20). 
This is supported in a study by Richardson et al (21), who reported that a number of 
cytokines including IL-1, IL-4, IL-8, IL-10, IFN-γ and TNF-α were increased in pregnant 
women living with HIV compared to uninfected pregnant women. Many of the important 
inflammatory cytokines that play a role in immune regulation during pregnancy have also 
shown to be deregulated with HIV infection. These particular cytokines go on to 
contribute to the elevated inflammatory environment expressed by the mothers. 
Furthermore, whether or not the immune system of the children is similar to that of their 
mothers is a critical area for further exploration, including potential mechanisms that 
underlie the concept of “intergenerational transmission”. Additionally, the transfer of 
inflammatory markers from the pregnant mother to the foetus is also poorly understood; 
it is uncertain if specific cytokines transfer directly through the placenta to the developing 
foetus or whether the mothers’ immune system “primes” the immune system of the 
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foetus. In addition, whether or not the altered immune system of the foetus persists once 
the child is born and begins to age is also uncertain. Studies conducted so far, which 
evaluate the immune system of HEU, express the vulnerability of their immune system 
(22). A comprehensive review by Abu-Raya et al indicates that HEU children have an 
increase in innate immune cytokine production (23).  
 
A number of studies have shown that MIA has an impact on the neurodevelopment of the 
foetus through increased levels of inflammatory cytokines (5–7,10); and may in turn lead 
to the development of neuropsychiatric disorders (9). The cause behind MIA in these 
studies varied, however the fact that there is a resulting increased level of certain 
inflammatory markers allows the connection between HIV, the immune system and 
neurodevelopment to be made.  
 
A recent meta-analysis by McHenry et al (4), which included 45 studies assessing 
neurodevelopment in HEU children, found that HEU children did have lower cognitive 
and motor scores than their HUU counterparts. However, many of the studies are limited 
to the evaluation of cognitive abilities of the children at a very young age, therefore 
whether these cognitive deficits persist later on in life is still unknown.   
 
Given the gaps outlined in the literature, the aims of the study are as follows: firstly, to 
investigate the impact of HIV on the inflammatory environment of the mothers during 
pregnancy. Secondly, to investigate the inflammatory environment of HEU children. 
Lastly, to assess whether adaptations in the inflammatory environment of the mothers and 
children is associated with impaired neurodevelopment of the children. Mother-infant 
pairs present within the Drakenstein Child Health Study (DCHS), the parent study, will aid 
in achieving these aims (24,25). 
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The significance of the current study lies in the gap in knowledge of the link between 
maternal HIV infection, the inflammatory environment of both the mother and infant and 
the neurodevelopment of the HEU children. By identifying changes in particular 
inflammatory markers as a result of HIV exposure and determining how these 
inflammatory markers play a role in neurodevelopment it may be possible to mitigate 
these neurodevelopmental disorders. Particularly in South Africa, where HIV is still rife and 
the numbers of HEU children are increasing, the demand to ensure that these children do 
not become susceptible to neurodevelopmental disorders in the future is critical.  
 
The thesis will comprise four further chapters, as follows:  
The first chapter will contain a literature review, where the impact of HIV on the immune 
system will be assessed, in particular the inflammatory environment, of both the mothers 
during pregnancy and the children. Following that, the impact of MIA on the 
neurodevelopment of the children will be examined, as well as the impact of HIV on the 
neurodevelopment of the children. The chapter will conclude with an outline of the gaps 
present within the literature and the hypotheses of the study.  
 
The second chapter describes the methods and materials used in this study. This section 
includes the characteristics of the study population, the recruitment criteria, the study 
design, research procedures and data collection. An outline of the statistical procedures 
used for analysing the results will also be included as well as an ethical statement.  
 
The third chapter will outline the results of the study. The fourth and final chapter will be a 
discussion to summarise these results and place them into context with the themes 
covered in the literature review. In addition, limitations will be discussed and future 
research prospects will be suggested, which could build on this study and our 
understanding of the link between HIV, the immune system and neurodevelopment in 
HEU children.  
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1. LITERATURE REVIEW 
This literature review aims to highlight the gaps of knowledge in scientific research 
regarding the impact of HIV on the inflammatory environment of pregnant mothers 
and their children, as well as the association between adaptations in the 
inflammatory environment with the neurodevelopment of the children.  
 
1.1 The impact of HIV on the inflammatory environment of the mother during 
pregnancy 
The immune system plays a critical role during pregnancy and the development of 
the foetus in utero. This section aims to assess the impact that HIV has on serum 
levels of inflammatory markers during pregnancy and how this consequently 
impacts the immune system of the foetus through intergenerational transmission. 
 
Immune regulation during healthy pregnancy without comorbidities 
The first trimester is a crucial period that oversees fundamental elements of both 
placental and foetal development; the placenta provides a powerful barrier 
protecting the foetus from infectious pathogens. The placenta is made up of 
chorionic villi (foetal capillaries and villous stroma) and trophoblast cells (26). The 
villi are covered with multinucleated fused syncytiotrophoblasts (SYN), which make 
direct contact with maternal blood (27). When SYNs are differentiated they 
become highly resistant to viral infection (28). The mothers’ immune system 
provides further protection to the foetus; SYNs express neonatal Fc receptors 
(FcRn) that transfer maternal immunoglobulin G (IgG) antibodies to the foetus (29).  
It has been shown that HIV affects the transfer of antibodies to the foetus. For 
example, if the mother has increased serum IgG levels, placental transfer of 
antibodies is impaired (30,31).  
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Trophoblast cells are immune cells within the placenta responsible for secreting 
cytokines. Along with other immune cells, cytokines secreted by the trophoblast 
cells in the placenta play a role in regulating the immune response during 
pregnancy. Cytokines are multifunctional pleiotropic proteins, which play a critical 
role in cell-to-cell communication and activation in a variety of physiological and 
pathological processes, particularly in regards to the immune response (32). During 
healthy pregnancy without comorbidities, the first trimester is postulated to 
provide a pro-inflammatory response in the mother as her body struggles to adapt 
to the presence of the foetus; however the second trimester highlights the 
induction of an anti-inflammatory state (33,34). Renewed inflammation occurs in 
the third trimester as the mother prepares to deliver the baby. Pro-inflammatory 
cytokines, including Interleukin-6 (IL-6) and Tumour Necrosis Factor-α (TNF-α) are 
found to be elevated during the onset of labour, however these same cytokines in 
excess can detriment the labour process (19). Anti-inflammatory cytokines such as 
IL-10 and IL-4 are also modulated in healthy pregnancy and have shown to be 
decreased as a result of maternal infection consequentially causing adverse 
pregnancy outcomes (34). 
 
Role of inflammatory markers in HIV infection 
Certain cytokines released by trophoblasts have the ability to up-regulate HIV 
expression and replication in infected cells (26). A high level of HIV transcripts is 
associated with elevated expression of inflammatory cytokines (26,35). HIV 
infection has also been associated with an increased risk for placental membrane 
inflammatory lesions (36). Studies conducted so far have predominantly focused on 
three pro-inflammatory cytokines, IL-1β, IL-6 and TNF-α, during pregnancy 
(21,35,37). These studies have expressed that these pro-inflammatory cytokines are 
significantly involved in immune regulation during pregnancy and are deregulated 
with HIV infection and in fact can enhance HIV replication (35). It is important to 
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note that a chronic inflammatory state present with HIV infection persists even 
when treated successfully with ART in the majority of studies conducted so far (17). 
An increase in inflammatory cytokines during pregnancy, which in turn is 
exacerbated due to infection with HIV, may impact the developing foetus.  
 
The pro-inflammatory cytokine TNF-α plays a critical role in pregnancy; it is 
associated with the inflammatory mechanisms that underlie implantation, 
placentation and pregnancy outcome as a whole (18). An increase in TNF-α has 
been associated with numerous adverse pregnancy outcomes including 
miscarriages, pre-eclampsia and preterm birth (18). Studies have shown that TNF-α 
is significantly increased during pregnancy in mothers living with HIV on ART who 
were both virologically unsuppressed (35,38) and suppressed (39). Another study 
conducted by Mikyas et al (20), reported that serum levels of TNF-α were 
significantly elevated during all time points throughout the three trimesters in 
pregnant women living with HIV with 67% of women treated with ART in 
comparison to uninfected pregnant women. It is unclear in this study whether these 
women were virologically suppressed.   
 
Elevated levels of IL-6 are observed in many chronic inflammatory and autoimmune 
disorders, including HIV, and often serves as a marker for the systemic activation of 
pro-inflammatory cytokines. IL-6 along with TNF-α has also been shown to be 
increased during healthy pregnancy (40), and then furthermore with HIV infection 
(35,41). IL-1β is another pro-inflammatory cytokine that has shown to be increased 
in placental cells of mothers living with HIV not treated with ART who were both 
virologically suppressed and unsuppressed, whereas secretion of IL-1β by 
trophoblast cells in uninfected mothers remained low and stable (41). Other 
cytokines that have shown to be increased inpregnant mothers living with HIV on 
ART who were virologically suppressed are IL-8 and interferon-γ  (IFN-γ) (21,39). 
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Contrastingly, a study by Maharaj et al (42), evaluating cytokine levels in pregnant 
women living with HIV and uninfected pregnant women with and without pre-
eclampsia reported lower levels of the inflammatory cytokines TNF-α, IL-2 and IL-6 
in mothers living with HIV compared with uninfected mothers. The women living 
with HIV were all treated with highly active antiretroviral therapy (HAART), which 
may have had an impact on the results. A study by Moussa et al (37), also found 
decreased levels of IL-6 in mothers living with HIV on ART. It is unclear in this study 
whether mothers were virologically suppressed.  
 
Further, pregnancy also has an effect on the pathology of HIV infection, for 
example a study by Sutton et al (43), revealed that pregnancy down-regulates the 
production of IL-2 in pregnant mothers living with HIV on ART who were 
virologically unsuppressed compared to mothers who are uninfected. This was not 
seen in the comparison of non-pregnant individuals living with HIV. The anti-
inflammatory cytokine, IL-10, has been shown to be secreted at higher 
concentrations in mothers living with HIV by Hofbauer cells and additionally has 
the ability to inhibit HIV replication in vitro (44). Notably, many of the studies in this 
section differ in regards to whether or not the mothers were treated with ART and 
whether they were virologically suppressed. These factors most likely impact the 
inflammatory environment of the mothers and outline a gap in the literature. 
Another factor to take into consideration is that the majority of the studies 
assessed have been conducted in western countries; this is important, as different 
countries possess different subtypes or clades of HIV infection, which can present 
different inflammatory profiles (45). The predominant subtype in South Africa is 






The transfer of inflammatory mediators to the foetus is less well understood. 
Intergenerational transmission refers to the concept that stress exposure in the 
mother has a direct impact on the children via changes to gametes and the 
gestational uterine environment (49). “Stress” can encompass numerous examples 
including HIV infection. The changes imposed on the gametes and the gestational 
uterine environment involves changes to the immune system and in the case of HIV 
result in an elevated inflammatory environment (44). Penetration of HIV viral 
particles, such as envelope glycoprotein (GP120), across the placental barrier even 
in the absence of foetal infection has been supported with experimental results 
(50,51).  A review by Abu-Raya et al substantiates the alteration that HIV has on the 
transfer of maternal immune factors to the infants and underlies the importance of 
investigating further the mechanisms behind this (52).  
 
Alterations that HIV poses on the transfer of maternal immune factors include 
immune activation in the pregnant mother living with HIV and its association with 
the production of inflammatory cytokines at the maternofoetal interface, which may 
lead to inflammatory responses in the infant (53). An extensive review of the 
placenta by Pasca and Penn posits that the placenta has the ability to produce its 
own array of cytokines that have the ability to enter the foetal circulation and 
thereby modulate foetal neurodevelopment (54). Morelli et al hypothesised that 
exposure of the foetus in utero to inflammatory cytokines, elicited by the mothers 
immune response, programs the immune system of the foetus; resulting in a “pro-
inflammatory phenotype” that may persist into adulthood and further be 
exacerbated by any sub-sequential exposure to an immune stimulus (10). Kakkar et 
al also puts forward this “two-hit” hypothesis, which elucidates that HEU infants 
may have an aberrant developmental outcome as a result of both a transferred 
state of immunodeficiency and a decreased placental transfer of protective 
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maternal antibodies due to HIV exposure in utero (55). This underlines the need to 
explore the extent to which the mothers’ immune system influences and predicts 
the immune system of their children and how this impacts their development. 
 
However, it is important to note that there are many other aspects that determine 
the outcome of the children’s immune system, including maternal antibodies, 
maternal diet and micronutrients and the maternal microbiome, to name a few (29). 
It is important to note that priming of foetal development in utero may in turn lead 
the children to respond inappropriately to the environment once born due to the 
fact that it is different to the environment for which it was prepared for in utero (8). 
Miyamoto et al suggests that the first postnatal year of life is the key period for 
programming the immune system of the children (56). This is supported by 
Prendergast et al, which stated that HEU infants have a sustained inflammatory 
phenotype until at least 6 months of age (57). A study conducted by Zaretsky et al 
reported that there is a bidirectional transfer of IL-6 across the placenta, indicating 
that the immune response of the mother does transfer to the foetus (58). Borges-
Almeida et al also indicated a high correlation of cytokine concentrations between 
the HEU infants and the mothers (59).  
 
On the other hand, a study by Aaltonen et al reported no transfer of cytokines from 
the mother to the foetus or vice versa, but did find an endogenous release of IL-6 
believed to be of foetal origin (60). Furthermore, a study by Lopez et al showed 
that there was no difference in foetal levels of IL-6 from mothers both living with 
HIV and uninfected, suggesting that an increase in inflammatory markers in women 
living with HIV may be an immune response isolated to the mother (61). Ultimately, 
the exact mechanisms behind the relationship of the mothers’ immune system to 
that of the foetus need further investigation.  
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1.2 The inflammatory environment of HIV-exposed uninfected (HEU) children 
Although HEU children are considered in the most part to be healthy, more 
research is proving that exposure to HIV in utero has an effect on their immune 
system (62),	 as hypothesised above through the concept of intergenerational 
transmission. Numerous studies so far have shown that there is an alteration in the 
immune system of the HEU children, particularly in the immune cell subsets, CD4 
and CD8, which have both been shown to be decreased in HEU infants (55,63,64). 
HIV exposure during pregnancy has also been associated with quantitative and 
qualitative changes in dendritic cells, which could also play a role in the abnormally 
increased T-cell activation (51). In addition, HEU children also show phenotypical 
differences; expressing a more antigen-experienced cellular phenotype, with 
expanded memory T-cell subsets and heightened immune activation with 
increased apoptosis (22). Despite numerous studies assessing the immune cell 
subsets in HEU children, fewer studies have investigated inflammatory markers, 
highlighting a gap in the literature.  
 
Expression of inflammatory markers in HEU compared to HUU children 
A study by Reikie et al that looked at cytokine production in monocytes stimulated 
with pathogen associated molecular patterns (PAMP) reported an enhanced pro-
inflammatory response of monocytes in HEU infants versus HUU infants; 
mononuclear cells from HEU infants produced more cytokine on a per-cell basis 
compared to their HUU counterparts; IL-12, IL-6 and TNF-α were all elevated in 
HEU infants (65). However, by 12 months of age any difference in reactivity 
between HEU and HUU mononuclear cells had disappeared completely (65). 
Contrastingly, Chougnet et al reported decreased levels of IL-12 in cord blood of 
HEU infants from mothers who were virologically unsuppressed compared to HUU 
infants (66). Cord blood IL-12 was correlated with maternal IL-12 implying that 
exposure to HIV in utero alters the quality of T-cell response and impacts foetal 
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immune development (66). Notably, mothers in these studies were treated with 
ART.  
 
Significantly increased levels of IL-8 and IL-1β were detected in the plasma of HEU 
infants with virologically suppressed mothers compared with HUU infants in a study 
conducted in the Netherlands by Bunders et al (62). Increased expression of 
inflammatory response-related chemokine receptors in HEU infants were also 
accounted for in the same study (62). A study by Miyamoto et al reported 
significantly increased levels of IL-4 in HEU children between the ages of 6 and 12 
years with mothers who were virologically unsuppressed; and therefore concluded 
that HEU children are not significantly immune compromised (56).  Another study 
by Borges-Almeida et al, however, reported decreased levels of IL-4 in HEU infants 
with mothers who were virologically unsuppressed (59). Increased levels of IFN-γ 
were also found in the same study. Similarly a study by Hygino et al also revealed 
significantly increased levels of IFN-γ as well as TNF-α in the cord blood of HEU 
infants with mothers who were both virologically suppressed and unsuppressed 
compared with HUU infants, they also found reduced levels of IL-10 in the HEU 
infants (67). Contrastingly, a study by Kuhn et al found significantly increased levels 
of IL-10 in HEU infants; although increased levels subsided by 6 months of age, 
however mothers in this study were not treated with ART unlike in the other studies 
mentioned (68).  
 
A study by Clerici et al showed that HEU infants expressed significantly increased 
levels of IL-7 compared to HUU infants at birth and later on, suggesting that 
changes in the immune system of HEU infants persist later on in life (50). 
Prendergast et al did not find a significant difference between cytokine levels of 
HEU and HUU infants but did find increased levels of C-reactive protein (CRP) in 
HEU infants, indicating that they still possess an elevated inflammatory 
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environment, mothers in this study were not on ART and were virologically 
suppressed (57). Additionally, peripheral blood cells of HEU infants were reported 
to proliferate and produce IL-2 after exposure to HIV (69). The variation in findings 
between the studies may be due to a number of factors including a difference in 
the age of the infants/children, their socioeconomic background, the subtype of 
HIV to which they were exposed, maternal HIV load, ART exposure, maternal 
microbiome and whether they had any other infections as well as differences in the 
number of participants in the relative studies. The variation in findings from the 
different studies included further indicates the complexity of the immune system in 
relation to HIV exposure.  
 
Mortality and morbidity in HEU children 
A number of studies evaluated the mortality and morbidity of HEU children and 
found that they do have an increased mortality rate and are more likely to contract 
infections (70–72). For example, Slogrove et al reported that twice as many HEU 
infants had at least one infection associated with hospitalization in the first year of 
life compared to HUU infants (71). Studies by Evans et al also support an increase 
in mortality and morbidity in HEU children compared with HUU children suggesting 
an impaired ability to control the infection (72,73). Furthermore, one study, which 
looked at Cytomegalovirus (CMV) acquisition and inflammation in HEU children, 
also reported a pro-inflammatory environment and higher CMV load in HEU 
children and an overall increase in mortality (73). Dirajilal-Fargo et al, also 
expressed that increased IL-6 at birth may contribute to increased HEU morbidity 
(74). On the other hand, studies have shown that inflammatory markers were not 
associated with mortality and morbidity in HEU children (57). The majority of 
studies evaluating mortality and morbidity in HEU children found that increased 
risk of contracting other infections led to the death of these children, this highlights 
the fact that the immune system of HEU children is most likely compromised.  
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Exposure to ARVs in HEU children 
It is important to note that HEU children are not only exposed in utero to HIV but 
also to ARVs, which may further contribute to adverse pregnancy outcomes (75). 
Certain ARVs such as Zidovudine (ZDV) have been implicated in mitochondrial 
toxicity due to inhibition of host cell gamma-polymerase and accumulation of 
somatic mitochondrial DNA mutations; which impact the development of the HEU 
children’s immune system (76). A study by Cassidy et al, in Botswana showed that 
exposure to efavirenz-based ART was associated with lower receptive language 
scores at 2 years of age as compare with HEU children with non-efavirenxz-based 
ART (77). Other studies, however, have found no impact of ART exposure in utero 
on neurodevelopmental outcomes in HEU children at 2 years of age (78,79). 
Ultimately, the impact of ART on the inflammatory environment and development 
of HEU children remains uncertain, particularly when these children have also been 
exposed to HIV in utero. However, the impact of ARVs is beyond the scope of this 
study, due to the fact that all mothers in this study were on ARVs as per standard 
treatment guidelines.  
 
1.3 The impact of maternal immune activation (MIA) on the neurodevelopment of 
their children. 
The impact of the immune system on the developing nervous system is an 
important emerging area of interest. Deregulation within the immune system may 
lead to neurodevelopmental or psychiatric disorders and visa versa; as suggested 
by Damman et al (80). Cytokines present in the amniotic fluid and foetal circulation, 
representing a foetal inflammatory response may increase the risk of injury to the 
developing brain. The studies evaluated in this section investigated MIA (not 
necessarily due to HIV) in relation to neurodevelopmental issues.   
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Impact of cytokines on glial cells 
Increased levels of inflammatory cytokines are suggested to have an impact on 
glial cells, such as astrocytes and microglia, which play a role in neurodevelopment 
(11,81). Astrocytes are important in neuronal development and repair, as well as 
synapse formation (82). Microglia are the immune cells of the CNS and have an 
ability to produce cytokines; they react to insult by transforming into amoeboid 
microglia that proceed to synthesize large amounts of inflammatory cytokines (5). 
The exposure of the foetus to infection resulting in amoeboid microglia can persist 
into postnatal life, exposing the brain of the post-natal child to the overexpression 
of inflammatory cytokines (5), particularly IL-1, IL-6 and TNF-α, these cytokines 
divert stem cells from neuronal differentiation and in turn increases apoptosis in 
neuronal and non-neuronal cells (6). IL-1, IL-6 and TNF-α are pleiotropic cytokines 
heavily involved in the CNS. TNF-α has been shown to influence neuronal 
progenitor cell proliferation and differentiation. IL-1 exerts functions in the CNS 
such as regulation of temperature, food intake and neuroendocrine function. IL-6 
co-stimulates the immune response by synergizing with TNF-α and IL-1 to result in 
B-cell replication, differentiation and immunoglobin production (83). IL-6 also plays 
a role in the hypothalamic-pituitary adrenal (HPA) axis function, reduction of food 
intake, induction of fever and neuronal growth (83).  
 
Additionally, cytokines are involved in most stages of neurogenesis including 
formation of the neural tube, synapses and dorsoventral domains, anteroposterior 
regionalization, specification of neuronal and glial phenotypes as well as the 
expression of neurotransmitters and receptors (7). It is even suggested that low 
levels of circulating inflammatory cytokines have the ability to influence complex 
brain functions (84). A review by Bilbo and Schwarz describes how increased 
cytokine exposure during critical periods of neurodevelopment may act as a 
“vulnerability” factor for psychiatric conditions later in life by sensitizing neural 
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substrates and altering the way the brain responds to further immune stimuli (85). It 
is also hypothesised that MIA may potentiate the effects of “risk” genes resulting 
in neuropsychiatric disorders (9). The CNS itself is also capable of producing 
cytokines during the inflammatory response; with the expression of IL-1, IL-6 and 
TNF-α being most prominent in the hypothalamus and hippocampus and less so in 
the cortex and brain stem regions (86). A profound example of how cytokines can 
impact brain function is through the expression of “sickness behaviour” outlined in 
a review by Dantzer et al where he explains how cytokines, particularly IL-1, TNF-α 
and IL-6, induce not only symptoms of sickness in response to infection but also 
major depressive disorders in patients with no previous history of mental health 
disorders (87). Overall the role of cytokines in the CNS and brain function and 
development is vast and complex; significant increases or decreases in levels of 
cytokines may therefore negatively impact important brain function.   
 
Impact of cytokines on the hypothalamic-pituitary adrenal (HPA) axis 
As well as the effect of MIA on cytokine levels, numerous other physiological 
effects may occur. Ratnayake et al proposes that an alternative mechanism by 
which an induction of pro-inflammatory cytokines can result in neurodevelopmental 
issues is through the HPA axis rather than through glial cells (11). An increase in 
cytokine levels, particularly IL-1 (6), can activate the HPA axis, responsible for the 
generalised stress response (88). Activation of the HPA axis results in the release of 
numerous glucocorticoids that may modify foetal brain development and 
permanently alter the function of the HPA axis in postnatal life (88). Excessive 
release of the hormones adrenocorticotropic hormone (ACTH) and corticotropin-
releasing hormone (CRH) can be detrimental to foetal development (2). It is 
important to note that dysfunction with the HPA axis is hypothesised to play a 
critical role in numerous psychological diseases, including depression (89).  
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Impact of cytokines on neurotransmitter systems 
Cytokines further impact neurotransmitter systems in the developing brain, altering 
their concentration or availability (90). For instance cytokine elevation due to 
inflammation can result in decreased survival of foetal serotonin neurons in the 
rostral raphe and increased expression of gamma-aminobutyric acid receptors in 
the amygdala (91). In addition, placental inflammation is also associated with 
disruptions to the tryptophan pathway in the placenta, which may have a 
corresponding effect on the production of serotonin and neural development (8). 
Furthermore, MIA can result in the production of reactive oxygen species (ROS) 
leading to oxidative stress that may induce neurotoxicity (92). Pro-inflammatory 
cytokines also trigger the induction of metallothionein, which may lead to zinc 
deficiency that can also contribute to poor developmental outcomes (92). 
Neurotransmitters are crucial in healthy brain function; it is well established that 
altered levels of neurotransmitters are present in numerous neuropsychological 
disorders for example individuals with depression often have alterations in 
serotonin, norepinephrine and dopamine (93).   
 
It is important to note that specific regions of the brain may be relevant to distinct 
neuropsychiatric disorders. A review by Estes et al also states the importance of 
timing in MIA; infection during early versus late gestational stages causes distinct 
foetal brain cytokine responses (12). Whether this in-turn leads to distinct 
neuropsychiatric disorders is still unclear. However, around the time of birth the 
neurodevelopmental process is particularly active within the portal and temporal 
cortices that go on to impact complex cognitive and social functions in the 
children, such as cell migration, organization and synaptic maturation (15,94). It is 
important to note that HIV affects the mother’s immune system and therefore the 
immune system of the foetus throughout the entire gestational period, making it a 
marked immune insult. 
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Role of MIA and cytokine expression in neurodevelopmental and psychiatric 
disorders  
A number of studies have been conducted using animal models to assess the 
impact of MIA on the neurodevelopment of the foetus, in stark contrast to the 
limited number of studies conducted in humans. It is crucial that more human 
based studies are done, because the relationship between the inflammatory 
environment of the mother to that of the foetus differs between species. A number 
of studies in animal models have highlighted a relationship between MIA and the 
development of neuropsychiatric disorders such as Schizophrenia and Autism 
Spectrum Disorder in adult offspring (13,95). However MIA has not been directly 
linked with specific neuropsychiatric disorders in humans but instead is 
hypothesised to prime the immune system of infants so that they are more 
susceptible to triggers that may cause the disorders later in life (12).  
 
One study conducted by Yoon et al did however report an association of higher 
concentrations of TNF-α, IL-1β and IL-6 with white matter lesions and cerebral palsy 
in newborns by measuring the amniotic fluid concentration of the respective 
cytokines (96). Furthermore, an epidemiological study conducted by Brown et al 
examined the role of prenatal infection in the development of Schizophrenia (14). 
In this study it was shown that an elevation in maternal levels of IL-8 during the 
second and third trimester was associated with increased risk of children 
developing Schizophrenia (14). It was also noted at the time of birth that TNF-α 
was significantly increased amongst mothers of children with psychosis (14). They 
did not find, however, an association between IL-1β, IL-6 and IL-2 with the 
development of neuropsychiatric disorders (14). As mentioned previously, the 
inflammatory markers IL-6, TNF-α and IL-1β, which have shown in previous studies 
to be elevated with HIV infection, also play a critical role in cognitive function.  
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Normal physiological levels of IL-1β, IL-6 and TNF-α play an important role in 
maintaining synaptic plasticity mechanisms in the brain, particularly memory 
function (97). Increased levels of IL-1β in the brain on the other hand are strongly 
correlated with memory impairment (97). Heightened levels of IL-1β have been 
reported in numerous neuropsychiatric disorders including AIDS related dementia 
and chronic inflammatory diseases such as Alzheimer’s Disease (98,99). IL-6 is 
expressed in the CNS under both pathological and normal conditions, however 
levels remain low in the intact brain (100). A study by Rudolph et al showed that 
maternal IL-6 levels (indicating maternal inflammation) during pregnancy are 
associated with differences in functional brain networks, specifically the sub-
cortical, salience and dorsal attention systems in the newborns and then negatively 
associated with working memory in the children at 2 years of age (101). This is of 
interest, since working memory is a core component of executive functioning that 
is deregulated in neuropsychiatric disorders such as autism spectrum disorders and 
schizophrenia.  
 
IFN-γ has been associated with CNS disease states such as multiple sclerosis and 
AIDS dementia complex (82). In addition, infection in the third trimester is linked 
with increased risk of developing autism spectrum disorder (15). A recent study by 
Graham et al is one of the first studies in humans that reported association of 
elevations of a specific mediator of maternal inflammation, IL-6, with the newborn 
brain (91). In summary, they found that heightened IL-6 levels in the mother 
correlated to an altered balance between the impulsivity and regulatory capacity of 
the newborn through alterations in the developing amygdala (91). The fact that 
they studied the brain shortly after birth also reduces potential confounding 
environmental impact (91). TNF-α has been shown to cross the blood brain barrier 
and reduce cerebral oxygen uptake resulting in intracranial pressure, making it a 
potent cytotoxic agent in neural tissue (102). In addition, substantial evidence is 
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present for microglial activation in the post-mortem brains of patients that suffered 
from a mental illness (103–105). This is of importance as we highlighted earlier that 
activated microglia are critical in the inflammatory process and play a role in 
secreting pro-inflammatory cytokines. In summary, this evidence supports the role 
of MIA and a pro-inflammatory environment in the development of 
neuropsychiatric disorders.  
 
1.4 The impact of maternal HIV on the neurodevelopment of HEU children 
This section will focus on studies specifically looking at maternal HIV infection and 
the neurodevelopment of the uninfected children. Cognitive decline in infants 
living with HIV has convincingly been associated with increased early HIV viral load 
and can therefore be linked with HIV infection (106). Maternal inflammation has 
been strongly associated with risk of preterm birth (34), which is also fairly common 
in mothers living with HIV (52,61). Preterm birth has, in turn, been associated with 
neurocognitive impairments (102). However, it is also hypothesised that detectable 
developmental delays among HEU children may, in part be a result of the 
environment and not of any direct biological consequence due to being exposed 
to HIV in utero (70). In the majority of studies conducted on HEU children, the 
primary measure of neurodevelopment of the children is through the Bayley Scales 
of Infant and Toddler Development (Bayley-III); this assessment is designed to 
measure developmental function through five different scales: Cognitive, 
Language, Motor, Social-Emotional and Adaptive Behaviour (107). It is important 
to note that the impact of HIV extends far beyond just the neurodevelopment of 
HEU children into areas such as physical along with mental health, education and 
exposure to stigma and household environment, which in many countries coincides 
with exposure to poverty (108). These factors most likely influence the 
neurodevelopment of HEU perhaps even more so than HIV exposure in utero and 
therefore need to be taken into careful consideration when conducting analyses.  
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Studies investigating neurodevelopment in HEU children using the Bayley-III 
Neurodevelopment in HEU children has been assessed in numerous studies, with a 
number of recently published reviews. The most extensive and up–to-date meta-
analysis by McHenry et al looked at 45 studies where the neurodevelopment of the 
HEU children in the various studies were assessed using the Bayley-III and found 
that HEU children had over-all lower cognitive and motor scores compared to HUU 
children (4). Another review by Le Doaré et al established that HEU children along 
with children living with HIV also demonstrated greater neurodevelopmental delay 
compared with HUU children, particularly when it came to language and adaptive 
behaviour below the age of 5 (109). Unfortunately, a lot of the studies conducted 
so far, including the ones evaluated within the above reviews do not have a control 
group of HUU children to compare results with. It is important to note that the 
majority of studies conducted so far have found impaired neurodevelopment in 
HEU children compared to HUU children.  
 
A study conducted by Le Roux et al in South Africa found increased odds of 
cognitive and motor delay in HEU infants compared to HUU infants (110). 
However, they did not find a delay in language scores and any 
neurodevelopmental impairment observed was not severe (110). Another study by 
Van Rie et al assessed neurodevelopment in HEU children in Kinshasa and found 
moderate to severe delay in motor and language development in a substantial 
amount of HEU children (111). It was also highlighted that the living conditions of 
these children played a critical role in their neurodevelopmental outcome (111). 
Furthermore, a study in China reported significantly lower composite scores, 
particularly cognitive and adaptive behaviour scores, in the Bayley-III assessment in 
HEU children compared to HUU children (112). Moreover, older HEU children (30-
	 33 
35 months) had the lowest neurodevelopmental level in comparison to younger 
HEU children in the same study (112).  
 
On the other hand, some studies did not find a significant difference in 
neurodevelopmental outcomes between HEU and HUU children using the Bayley-
III. A study by Alimenti et al found that perinatal HAART-exposed HEU children 
had lower adaptive behavioural outcomes in comparison to HUU, however this 
significance was lost after controlling for substance abuse (113). Furthermore, a 
study by Chaudhury et al found HEU children at 24 months performed equally well 
on neurodevelopmental assessments in comparison to HUU children (114). 
Springer et al performed a study comparing neurodevelopment using the Bayley-III 
scale and Alarm Distress Baby Scale (ADBS), between HEU and HUU infants in a 
peri-urban area of South Africa (115). They found the cognitive, language and 
motor scores were within average range and only found minor differences in 
vocalization and social withdrawal between the two groups indicating no significant 
difference. As mentioned previously there are numerous factors that play a role in 
the neurodevelopment of HEU children; discrepancies between these studies may 
be due to ART exposure, stigma and socio-economic status.  
 
Studies investigating neurodevelopmental impairment in HEU children using 
alternative methods to the Bayley-III  
Alternatively, many studies examined the neurodevelopment of HEU children 
through numerous other methods than the Bayley-III. A systematic review 
conducted by Sherr et al, which assessed neurodevelopment in HEU children 
compared to HUU children concluded that HEU children are worthy of concern and 
points out, albeit tentatively, that HEU children are functioning below HUU children 
on numerous developmental, behavioural and cognitive parameters (116). This 
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review included studies that assessed neurodevelopment through both the Bayley-
III and other standardised neurodevelopmental assessments.  
 
A study by Kerr et al demonstrated that HEU children have modest but significant 
reductions in verbal IQ and full-scale IQ and Stanford-Binet Bead Memory scores 
(which assesses non-verbal fluid reasoning) compared with HUU children (117). 
They did however find no difference in performance IQ, sentence, digit or object 
memory (117). A study by Tran et al looked at white matter microstructural integrity 
in the brains of HEU newborns compared with HUU newborns and found higher 
fractional anisotropy in the middle cerebellar peduncles of HEU newborns 
compared with HUU newborns using Diffusion Tensor Imaging (DTI) (118). DTI 
gives insight into white matter microstructure and organization by tracking the 
diffusion of water molecules through white matter tracts of the brain; indicating a 
compromise in white matter microstructural integrity in HEU newborns (118). 
Cerebral changes are common in the last trimester; therefore, structural alterations 
that occur at this time may result in motor and cognitive deficits later in life (118).  
A study looking at academic achievement scores of children living with HIV and 
HEU children reported that the global and cognitive index scores of both groups 
were in the low average to average range of intellectual functioning compared to 
normative means across academic domains (119).  
 
Studies that found no difference in neurodevelopment between HEU and HUU 
children include a study conducted by Rajan et al on a cohort of HEU children in 
Dehli, which found that no neurodevelopmental impairment in HEU children using 
the Development Assessment scale for Indian Infants (DASII) (120). However 
neurodevelopmental impairment was associated with socioeconomic status and 
presence of wasting in both HEU and HIV infected children (120). The authors 
concluded that HEU children will develop normally with sufficient care, whereas 
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children living with HIV will continue to have delayed development despite 
optimum care. A study measuring the IQ between HUU and HEU children found 
that they did not differ in IQ scores (121). Additionally, no significant differences 
were detected in brain volume and DTI metrics between HUU and HEU children 
(121). Another study by Kandawasvika et al examining neurodevelopmental 
impairment between HEU, HUU and children living with HIV using the Bayley Infant 
Neurodevelopmental Screener (BINS) found that the percentage of children with a 
high risk for impaired neurodevelopment was no different between HEU and HUU 
but both these groups had significantly less chance of neurodevelopmental 
impairment compared to children living with HIV (122). They did however find an 
increase in neurodevelopmental impairment from 3 months to 9 months despite 
being infected, exposed or unexposed to HIV (122). Springer et al performed a 
pilot study in South Africa to assess the neurodevelopment of HEU children in 
comparison to HUU children using the Griffiths Mental Developmental Scales 
(GMDS), which measures locomotor, personal/social, hearing and speech, eye and 
hand coordination and performance (123). In this study they found no significant 
differences between the groups apart from the personal/social subscale where the 
HEU children performed significantly more poorly.  The use of these different 
studies highlight important gaps in the literature and indicate that there may be 
differences in IQ as well as brain connectivity and structure between HEU and HUU 
children.  
 
Studies evaluating the impact of ARVs on the neurodevelopment of HEU children 
ARVs have had a massive impact on reducing the vertical transmission of HIV to 
the infants and more common than not pregnant mothers are now being treated 
with ART. The effect of ART on the children is therefore, in addition to HIV 
exposure, not fully explored. However, the majority of studies conducted so far 
have not indicated any significant negative impacts. The following studies looked 
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specifically at the impact that ART has on the neurodevelopment of HEU children. 
A study assessing the impact of the ARV Zidovudine (ZDV) in comparison to a 
placebo in pregnant mothers yielded results reflecting that there was no significant 
difference in cognitive function between the children of the two groups (treatment 
with ZDV vs. treatment with a placebo), suggesting that ARVs don’t significantly 
impact neurodevelopment (124). It is important to note that this study assessed 
cognitive outcome in the same children every year up until the age of 4 (with 
intention to continue to age 21, and has reported no significant health or cognitive 
impairments so far (124). A European collaborative study also agrees that ART 
exposure in HEU children does not have a negative impact on their 
neurodevelopment, but did find a correlation of ART with premature birth (125). 
Another study by Williams et al assessing neurodevelopment also found no 
significant differences between HEU and HUU children at 2 years of age, only 
slightly higher scores for HEU children were observed using the Bayley-III scale but 
no difference was seen on the Mental Developmental Index and Psychomotor 
Developmental Index scores (126).  
 
A study by Ngoma et al assessing the neurodevelopment of HEU compared to 
HUU infants exposed to ART in utero and then later on through breastfeeding also 
established no cognitive or language impairment, using the Capute Full-Scale 
Developmental Quotient (FSDQ) (127). They did however find that a lower FSDQ 
score, indicating neurodevelopmental impairment, was associated with lower birth 
weight and lower family income (127). A study conducted on 5-13 year old HEU 
children who had in utero or neonatal exposure to ART found that their cognitive 
and academic outcomes, assessed using the Weschsler intelligence and academic 
scales, were slightly below average but not significant; this indicated that there is 
no latent onset of neurodevelopmental impairment in children (128).  No individual 
ARV drug was associated with neurodevelopmental impairment in this study, 
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supporting the safety of ART (128). A longitudinal study by Smith et al assessed 
verbal, performance and full-scale IQ as well as language in HEU children exposed 
to ART (129). At 3.5 and 5.5 years of age they found that at both ages the scores 
were within the normal range. However despite their average scores in these 
cognitive developmental aspects their scores in adaptive function, including 
Adaptive Behaviour Composite and Socialisation scores, were significantly lower 
than average (129).  
 
Sirois et al conducted a study on infants ranging from 9-15 months, which all 
completed the Bayley-III and found that not one parameter of this assessment was 
associated with ART exposure, except for the individual drug Atazanir which was 
associated with language delay, overall this study supported the safety of ART 
(130).  One other study also found an association of the ARV drug Atazanir with 
language deficits in 1-year old infants. However, no individual ARV drug was 
associated with language deficits in 2 year-olds in the same study (131). A review 
by Heidari et al on ARVs and their effects on HEU children concluded that the 
benefits that ARVs have on the health and survival of the mother far outweighs any 
potential adverse effects identified to date (132). It is important to note that these 
studies may not be taking into consideration the impact of HIV exposure in utero 
rather than ARV exposure into their assessment on neurodevelopment of HEU 
children, however it is important to highlight their potential role.  
 
1.5 Hypotheses and aims 
Based on the literature review, 3 main gaps were identified. Firstly, more insight is 
needed surrounding the impact of HIV infection on the immune system of HIV 
positive pregnant mothers. Secondly, the immune system and serum levels of 
inflammatory markers of HEU children need further investigation. Finally, it is 
critical to further evaluate the association of inflammatory markers with 
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neurodevelopment in this population. Ultimately, the aim of this study was to 
delineate the relationship between the immune system of pregnant mothers living 
with HIV and their children, as well as the association between inflammatory 
markers and neurodevelopment in HEU children.  
 
The hypotheses were that: 
1. Pregnant mothers living with HIV would show increased levels of 
inflammatory markers compared to uninfected mothers. 
2. HEU infants and children will have increased levels of inflammatory markers 
compared to HUU infants and children, suggesting that the mother’s 
immune system predicts the immune system of their children  
3. Increased serum levels of inflammatory markers in HEU children will be 


















2.1. Characteristics of the study population 
Recruitment for the parent study: the Drakenstein Child Health Study (DCHS) took 
place from 2012 to 2015 in the Drakenstein peri-urban region of the Western 
Cape, South Africa. Like many peri-urban regions in South Africa it is characterized 
by a high prevalence of risk factors for poor child health such as HIV. Whilst there is 
a high prevalence of disease, there is access to well-established free primary health 
care services including 23 clinics and 1 hospital (25). Two of the primary health care 
clinics, TC Newman clinic and Mbekweni clinic, were used to recruit participants for 
the DCHS. Obstetric care was provided at Paarl Hospital where all births took 
place. In summary, these characteristics were ideal for recruitment of pregnant 
mothers with and without HIV infection as well as HEU children.  
 
2.2. Recruitment criteria 
In the DCHS n=1137 pregnant women between 20 and 28-weeks’ gestation were 
recruited by the DCHS staff at an initial antenatal visit as part of the parent study. 
Pregnant women were successfully enrolled if they were at least 18 years of age, 
planned to live in the region for at least 1 year and provided written signed 
consent (24,25). Out of the women recruited for the DCHS a sub-sample of 267 
women were selected based on availability of follow-up serum samples and their 
HIV status that reflects the whole DCHS sample. As this study is nested in the 
DCHS (24) the time points at which the serum samples were taken (26 weeks 
gestation for the mothers and 6-10 weeks and 24-28 months for the children) was 
already established. These time points are advantageous as it allows the evaluation 
of neurodevelopment longitudinally up up to 2 years of age, which is suggested to 
be a crucial time period in neurodevelopment. Study numbers for this sub-sample 
are represented in Tables 1, 2 and 3.  
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2.3. Study measures, Design, Research Procedures and Data Collection 
Blood sample collection and processing 
Blood serum samples were taken at 26 weeks gestation for mothers and at 6-10 
weeks and 24-28 months for children as outlined in the DCHS (3). Bloods were 
collected in serum tubes and allowed to clot for 30-60 minutes. Samples were 
transported on ice and processed in a central research laboratory. The samples 
were subject to 2 freeze/thaw cycles, which have no effect on cytokine levels (133). 
There was no reported problem with the collection, transportation and processing 
of blood samples.  
 
Laboratory analysis of cytokines 
For this thesis serum inflammatory markers, Lcn2 and MMP9, were quantified using 
commercially available ELISA kits (R&D systems) (134,135) in serum samples from 
the mothers and children. In addition, a premixed 13-plex – Immunology Multiplex 
Assay, known as MILLIPLEX® (136) was used to analyse other pro-inflammatory 
markers (GM-CSF, INF-γ, IL-1β, IL-2, IL-5, IL-6, IL-7, IL-8 and TNF-α) and anti-
inflammatory markers (IL-4, IL-10, IL-12 p70 and IL-13) on the same blood samples, 
using the Luminex® immunoassay reader. All samples were tested in duplicate. 
There were no reported problems with the testing standards and calibration of the 
immunoassay reader.  
 
Neurodevelopmental assessment 
Neurodevelopment of the children at 24-28 months was assessed with the Bayley 
Scales of Infant and Toddler Development (Bayley-III) assessment (107,137). 
Trained assessors involved in the DCHS captured this existing data, which was then 
used in data analysis for this thesis. The Bayley-III assessment is a well-validated 
tool that encompasses numerous scales to test for cognitive, language, motor, 
social-emotional and adaptive behaviour impairments from 1-42 months (107). A 
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trained physiotherapist and a trained occupational therapist were blinded to 
maternal HIV status and performed the Bayley-III testing. Training was performed 
in accordance with the Bayley-III manual by a pediatric neurodevelopmental 
specialist who periodically monitored the assessors throughout the testing period 
to validate standardized data collection across sites and ensure agreement 
between assessors on both administration and scoring. The assessors alternated 
between the TC Newman and Mbekweni clinics and assessed equal number of 
children at each site. Assessments were performed with prompts in the child’s 
preferred language. Neurodevelopmental assessments were not conducted on 
children when they had a fever, these children were then asked to return when 
possible. External scoring quality control checks were also performed centrally 
before data capture. For the current study standardized composite scores were 
used. Composite scores were generated for each cognitive, language, motor, 
social-emotional and adaptive behaviour domains, with a mean of 100 and 
standard deviation of 15, using normative United States data. The use of these 
composite scores has been validated in the South African setting (138,139). There 
were no adaptations to the social-emotional and adaptive behaviour domains. 
	
Variable measures and collection 
All variable measures and covariates mentioned in this section were captured by 
study staff involved in the DCHS and were used in the data analysis conducted in 
this study. Covariates included data on maternal demographics and health. This 
included residential area, education, HIV status, smoking, alcohol use, age and 
socioeconomical status, this data was obtained at enrolment. Maternal body mass 
index (BMI) was determined at 6–10 weeks postpartum. Data for mode of delivery, 
gestational age, infant sex, birth weight and length were obtained at the time of 
delivery at Paarl Hospital, where all births took place. Gestational age was 
calculated using the best estimated delivery date based on the last menstrual 
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period, antenatal ultrasound, or symphysis-fundal height. Prematurity was defined 
at less than 37 weeks gestation. Maternal CD4 cell count and viral load during 
pregnancy were measured, with the result closest to 26 weeks gestation taken to 
coincide with the immune variables. Viral load was categorized as below the 
detectable limit with <40 copies/ml, detectable with 40-1000 copies/ml and 
unsuppressed with >1000 copies/ml. All mothers living with HIV received 
antiretroviral therapy (ART) during pregnancy according to PMTCT guidelines at 
the time. Maternal ART initiation was categorized as ‘before pregnancy’ or ‘during 
pregnancy’. All HEU infants received prophylaxis (nevirapine alone or combined 
with zidovudine) from birth. (24,25). 
 
Information on breast-feeding practice and the presence of a fever were obtained 
at infant follow-up visits at 4-12 weeks, and 20-28 months of age. Breastfeeding 
was categorized as breastfeeding only vs. formula, solids feeding or their 
combination with breastfeeding. None of the children were breast fed at 24-28 
months of age (24,25).  
 
Socioeconomic status was determined via a sociodemographic questionnaire that 
was adapted from items used in the South African Stress and Health Study (SASH) 
(140). Mothers self-reported employment status, education level, asset ownership, 
household income and clinic during an antenatal study visit between 28 and 32 
weeks gestation (24,25). 
 
Maternal alcohol use during pregnancy was assessed using the Alcohol, Smoking, 
and Substance Involvement Screening Test; mothers were classified with either 
moderate-severe alcohol exposure vs. un-exposed. Infants and children were 
classified as being alcohol-exposed in utero if their mother was classified with 
moderate-severe alcohol exposure (24). 
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Smoking was determined through the measure of cotinine levels in the blood using 
the IMMULITE 1000 nicotine metabolite kit (141). An individual was considered a 
non-smoker if cotinine levels were <10ng/ml, a passive smoker with levels between 
10-500ng/ml and an active smoker with levels >500ng/ml (25). This data is 
summarized in Table 1.  
 
2.4. Data Safety and Monitoring 
Criteria for adverse events and potential harms were explicated in the parent 
study, which has been approved by the UCT HREC (HREC 401/2009 and HREC 
648/2018). Expected adverse events in human subjects was not relevant for this 
sub-study.  
 
2.5. Statistical Analysis 
All analyses were conducted using SPSS (version 25, IBM, USA). P-values were 
considered statistically significant for all analyses at a value of less than 0.05. 
Because of the skewed distribution, all markers were ln-transformed and used for 
further statistical analyses. As some covariates had missing data, we imputed 
values estimated from all predictor variables. Statistical analyses were performed 
on five imputed datasets. Variables with missing values were: delivery method 
(n=17), smoking status (n=8), alcohol use (n=14), socioeconomic status (n=5), BMI 
at 6 weeks (n=51), breastfeeding at 6-10 weeks (n=20) and finally birth weight 
(n=2). Data were complete for all other covariates. First, unpaired t-tests were used 
to explore the differences of the inflammatory markers in mothers during 
pregnancy, infants and children according to maternal HIV status. Linear regression 
analyses were subsequently performed with the respective markers as dependent 
variables, maternal HIV status as predictor and the covariates as previously 
described and was adjusted for multiple comparisons. Pearson’s correlations were 
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used to explore the associations between the inflammatory markers at each time 
point with neurodevelopment measures at 24-28 months of age. Regression 
analyses were further performed on significant findings with the respective 
inflammatory markers as dependent variables, neurodevelopment measure as 
predictor and controlled for by covariates and adjusted for multiple comparisons. 
The Benjamini-Hochberg procedure was used to control for the false discovery rate 
due to multiple testing (142). This procedure was used because it is less 
conservative than the Bonferroni correction method and is also more appropriate 
to control for false discovery rate. The Benjamini-Hochberg method p-values are 
ordered by ascending values according to the number of tests that were 
performed and accepted or rejected based on the adjusted p-values. Each 
individual p-value is compared to its Benjamini-Hochberg critical value (i/m)Q, 
where i is the rank, m is the total number of tests, and Q is the false discovery rate. 
The largest p-value that has p<(i/m)Q is accepted as significant and all the other 
subsequent smaller p-values in the order. According to the Benjamini-Hochberg 
some of the p-values were considered as false-positives. However, these findings 
cannot be ignored and should only be interpreted with caution.  
 
2.6. Ethics Statement 
The study was conducted in accordance with the Declaration of Helsinki (World 
Medical, 2000) and approved by the Human Ethics Research Committee of the 
Faculty of Health Sciences at the University of Cape Town (HREC 401/2009 and 
HREC 648/2018). The study was part of a parent study known as the Drakenstein 
Child Health Study (DCHS). In the parent study written informed consent was 
obtained from the mothers (older than or equal to 18 years), in their preferred 
language, on behalf of herself and her infant. Mothers were then given copies of 
their consent forms. All paper-based records of participant information are stored 
in a secure location and are only accessible to study staff involved in the DCHS. A 
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copy of each consent form is locked in a fireproof filing cabinet, which is only 
accessible to study staff. Study staff of the proposed study have password 
regulated access to computer data involving participant information. Additionally, 
all participants have been allocated anonymous numeric codes, and the actual 
identities of mother-infant pairs was not available to the student investigator. Thus, 


















3.1.   Participants  
Table 1 presents demographic data for the mothers living with HIV and uninfected 
mothers included in the study. There was a significant difference in the site where 
the women were recruited (p<0.001), with more women living with HIV being 
recruited from Mbekweni and more HIV uninfected women being recruited from 
TC Newman. Additionally, there were significantly more women living with HIV 
with moderate-severe alcohol exposure compare to uninfected women (p=0.032).  
 
Table	1:	Descriptive	demographic	characteristics	for	mothers	living	with	HIV	and	uninfected	mothers	
MOTHERS Living with HIV  Uninfected  P-value 
N (%) 77 (28.8) 190 (71.2) 0 
Age, mean (SD) 29 (5.43) 26 (5.87) 0.377 




































BMI, mean (SD) 28.81 (6.60) 26.23 (6.06) 0.551 
Viral load during pregnancy, N (%) 
Below detectable limit (<40 
copies/mL) 
Detectable (≥40-1000 copies/mL) 










CD4+ count during pregnancy, median 
(range) 
453.50 (339.25-628)   
Antiretroviral regimen during 
pregnancy, N (%) 
Prevention of mother-to-child 
transmission prophylaxis (zidovudine) 
First-line triple therapy 




























Nicotine Users (cotinine levels ng/ml), N 
(%) 
Non-smoker (<10ng/ml) 
Passive smoker (10-500 ng/ml) 






















Illness during pregnancy, N (%) 11 (13.9) 17 (8.9) 0.213 



























<37 weeks, N (%) 








Birth weight, mean (SD) 3.02 (0.52) 3.02 (0.59) 0.202 

























Table 2 presents data for the HUU and HEU infants at 6-10 weeks included in the 
study. There was a significant difference between HUU and HEU infants who were 
breastfed at 6-10 weeks (p=0.032), with significantly more HUU infants being 
breastfed compared to HEU infants. 
 
Table	2:	Descriptive	demographic	characteristics	for	HEU	and	HUU	infants	at	6-10	weeks	
INFANTS 6 WEEKS HEU HUU P-value 
N (%) 63 (71.6) 159 (28.4)  
Age (weeks), mean (SD) 8.1 (1.5) 7.9 (1.6) 0.277 
Weight, mean (SD) 4.91 (0.70) 4.83 (0.79) 0.505 
Length, mean (SD) 54.75 (2.66) 54.67 (2.90) 0.370 
Head circumference, mean 
(SD) 
38.86 (1.54) 38.61 (1.81) 0.197 
Breast-fed, N (%) 30 (45.5) 110 (60.8) 0.032 
Fever, N (%) 0 (0.0) 2 (1.1) 0.366 
*Significant difference between groups (P<0.05), SD = Standard deviation, N = numbers 
 
Table 3 presents data for the HUU and HEU children at 24-28 months, where no 
significant differences were found between the two groups.  
 
Table	3:	Descriptive	demographic	characteristics	for	HEU	and	HUU	children	at	24-28	months	
INFANTS 24 MONTHS HEU HUU P-value 
N (%) 77 (28.8) 190 (71.2)  
Age (months), mean (SD) 27.3 (4.0) 27.2 (3.5) 0.331 
Weight, mean (SD) 11.98 (1.88) 11.61 (1.63) 0.249 
Length, mean (SD) 83.40 (3.65) 83.73 (3.54) 0.889 
Head circumference, mean (SD) 48.43 (2.15) 47.96 (1.89) 0.858 
Breast-fed, N (%) 0 0 N/A 
Fever, N (%) 5 (6.6) 16 (8.4) 0.582 







3.2.    Inflammatory markers of mothers, their infants and children according to 
maternal HIV status    
Figure 1 presents the serum levels of the inflammatory markers GM-CSF (p=0.003) 
and MMP9 (p<0.001), which both proved to be significantly decreased in mothers 
living with HIV compared to uninfected mothers. The inflammatory markers IL-1β 
(p=0.021) and IL-4 (p=0.019) were also shown to be significantly decreased in 
mothers living with HIV initially, however this significance did not survive the 
corrections for multiple comparisons. Appendix 1 presents the ln-transformed 
























































Figure 2 presents the serum levels of the inflammatory markers IFN-γ (p=0.006) 
and IL-1β (p=0.006), which both proved to be significantly decreased in HEU 
infants compared to HUU infants at 6-10 weeks of age. The inflammatory markers 
IL-12p70 and IL-4 did initially show to be significantly decreased in HEU infants but 
did not remain so after corrections for multiple comparisons. Appendix 2 presents 
the ln-transformed values for all the inflammatory markers for HEU and HUU infants 


























































Figure 3 presents the serum levels of inflammatory markers for HEU and HUU 
children at 24-28 months; the inflammatory markers IFN-γ  (p=0.005), IL-1β 
(p<0.001), IL-2 (p=0.004) and IL-4 (p=0.013) were all shown to be significantly 
decreased in HEU children compared with HUU children after corrections for 
multiple comparisons. Appendix 3 presents the ln-transformed values for all the 









































































Table 4 shows the linear regression analysis for differences in inflammatory markers 
between mothers living with HIV and uninfected mothers and their HEU and HUU 
infants and children, corrected for potential covariates. Our results show that GM-
CSF (p=0.016) and MMP9 (p=0.034) remained significantly decreased in mothers 
living with HIV after correcting for covariates. IFN-γ (p=0.001)remained significantly 
decreased in HEU infants, however IL-1β (p=0.120) was not significant after 
controlling for all covariates. Our results further show HEU children had decreased 
IFN-γ (p=0.019), IL-1β (p=0.001), IL-2 (p=0.035) and IL-4 (p=0.017) levels after 





 B (SE) β p 
Mothers*    
GM-CSF -0.303 (0.15) -0.150 0.016 
MMP9 -0.243 (0.11) -0.150 0.034 
Infants 6-10 weeks#    
IFN-γ -0.544 (0.17) -0.251 0.001 
IL-1β -0.201 (0.16) -0.101 0.120 
Children 24-28 months†    
IFN-γ -0.237 (0.10) -0.180 0.019 
IL-1β -0.391 (0.12) -0.242 0.001 
IL-2 -0.204 (0.11) -0.130 0.035 
IL-4 -0.350 (0.161) -0.158 0.017 
* covariates:  residential area, education, smoking, alcohol use, age, socioeconomic status and body mass 
index (BMI) at 6–10 weeks postpartum. #covariates: Residential area, fever at time of visit, maternal 
smoking during pregnancy, maternal alcohol use during pregnancy, gestational age, maternal 
socioeconomic status and body mass index (BMI) at 6–10 weeks postpartum, premature birth, birth weight, 
infant sex and breastfeeding at 6-10 weeks. †covariates: Residential area, fever at time of visit, maternal 
smoking during pregnancy, maternal alcohol use during pregnancy, premature birth, maternal 
socioeconomic status and body mass index (BMI) at 6–10 weeks postpartum, gestational age, birth weight 






3.3.   Association of inflammatory markers with neurodevelopment 
Table 5 presents correlation analysis of inflammatory markers and neurodevelopment measures carried out on uninfected 
mothers. No inflammatory markers proved to be significantly associated with any of the neurodevelopment measures once 
corrections for multiple comparisons were applied. However, the inflammatory marker IL-8 (p=0.029, r=0.164) did initially 
show to be significantly associated with the cognitive neurodevelopment measure.  
	
Table	5:	Correlation	analysis	between	inflammatory	markers	in	uninfected	mothers	with	neurodevelopment	measures	in	their	children	at	24-28	months	
  GM-CSF IFN-γ IL-10 IL-12p70 IL-13 IL-1β IL-2 IL-4 IL-5 IL-6 IL-7 IL-8 TNF-α Lcn2 MMP9 
Cognitive r -.066 -.002 -.030 -.051 .048 -.017 -.031 .035 -.016 .016 -.072 .164* .039 .003 .054 
p-value .383 .980 .687 .500 .520 .817 .676 .638 .828 .834 .336 .029 .609 .969 .477 
Language r -.076 -.051 -.020 -.093 .043 -.033 -.017 -.004 .063 .002 .011 .123 .014 -.038 -.045 
p-value .326 .512 .800 .228 .580 .667 .828 .961 .415 .983 .887 .110 .855 .627 .564 
Motor r -.036 .026 -.004 -.034 .003 .060 .000 .076 .001 -.011 .023 .112 .058 -.030 -.014 
p-value .635 .727 .955 .650 .968 .432 .996 .315 .986 .888 .764 .138 .441 .693 .853 
Socio-emotional r -.046 .021 .054 .044 .008 .028 .024 .035 .041 .059 -.032 -.009 .050 -.051 -.048 
p-value .541 .779 .475 .558 .918 .710 .745 .646 .583 .435 .667 .900 .502 .496 .521 
Adaptive Behaviour r -.120 -.087 -.052 -.125 -.034 -.001 -.081 -.004 .009 -.024 -.080 .071 .040 -.053 -.088 








Table 6 presents correlation analysis of inflammatory markers and neurodevelopment measures in mothers living with HIV. 
Inmothers living with HIV, IFN-γ (p=0.014, r=-0.295), IL-10 (p=0.036, -0.253), IL-12p70 (p=0.030, r=-0.262) and IL-7 
(p=0.041, r=-0.246) did prove initially to be associated with the language neurodevelopment measure prior to corrections. 
TNF-α (p=0.014, r=-0.288) also showed to be significantly associated with the cognitive measure prior to corrections. The 
socio-emotional measure was initially associated with the inflammatory markers IL-10 (p=0.014, r=-0.295), IL-12p70 




  GM-CSF IFN-γ IL-10 IL-12p70 IL-13 IL-1β IL-2 IL-4 IL-5 IL-6 IL-7 IL-8 TNF-α Lcn2 MMP9 
Cognitive r .085 -.131 -.069 -.045 -.051 -.023 -.086 .049 -.128 -.144 -.226 -.071 -.288* -.016 -.122 
p-value .477 .272 .566 .705 .669 .850 .475 .684 .283 .227 .057 .556 .014 .892 .307 
Language r -.142 -.295* -.253* -.262* -.174 -.223 -.232 -.208 -.211 -.204 -.246* -.128 -.206 .081 .045 
p-value .245 .014 .036 .030 .153 .066 .056 .086 .081 .093 .041 .295 .089 .509 .711 
Motor r .031 -.166 -.147 -.164 -.082 -.133 -.085 -.123 -.134 .012 -.109 -.029 -.138 -.036 -.068 
p-value .807 .182 .240 .189 .511 .288 .496 .325 .283 .923 .383 .815 .269 .775 .589 
Socio-emotional r .042 -.182 -.270* -.262* -.087 -.214 -.186 -.186 -.120 -.240* -.167 -.210 -.103 .011 -.173 
p-value .729 .126 .022 .026 .467 .071 .118 .117 .317 .042 .161 .077 .388 .929 .147 
Adaptive Behaviour r .043 -.212 -.184 -.204 -.181 -.147 -.225 -.177 -.138 -.200 -.213 -.109 -.169 .084 -.019 







Table 7 presents correlation analysis of inflammatory markers and neurodevelopment measures in HUU infants at 6-10 
weeks of age. No significance was found with any of the inflammatory markers after corrections. However, the cognitive 
measure was initially associated with the inflammatory marker IL-1β (p=0.042, r=-0.169). The language measure was also 
initially significantly associated with the inflammatory markers IL-1β (0.004, r=-0.245), IL-2 (p=0.037, r=-0.178), IL-7 
(p=0.029, r=-0.186) and MMP9 (p=0.038, r=-0.178).  
 
Table	7:	Correlation	analysis	between	inflammatory	markers	in	HUU	infants	at	6-10	weeks	with	neurodevelopment	measures	at	24-28	months	
  GM-CSF IFN-γ IL-10 IL-12p70 IL-13 IL-1β IL-2 IL-4 IL-5 IL-6 IL-7 IL-8 TNF-α Lcn2 MMP9 
Cognitive r -.095 -.097 -.058 -.127 -.145 -.169* -.120 -.048 -.075 -.096 -.080 -.058 -.048 -.064 -.067 
p-value .253 .243 .485 .128 .081 .042 .149 .564 .370 .251 .341 .490 .568 .446 .424 
Language r -.100 -.115 -.051 -.165 -.090 -.245** -.178* -.066 -.140 -.150 -.186* -.036 -.069 -.137 -.178* 
p-value .244 .181 .552 .053 .296 .004 .037 .443 .102 .080 .029 .679 .420 .112 .038 
Motor r -.044 -.018 -.048 -.140 -.095 -.105 -.148 -.072 -.131 -.077 -.096 .011 .010 -.062 -.117 
p-value .600 .829 .569 .093 .257 .209 .075 .393 .117 .358 .252 .896 .904 .462 .164 
Socio-emotional r -.085 .020 -.113 -.094 .004 .016 -.044 .005 -.027 -.059 -.041 -.038 .068 .010 .018 
p-value .307 .807 .175 .257 .961 .853 .597 .951 .748 .478 .628 .646 .416 .903 .828 
Adaptive Behaviour r -.022 -.006 -.063 -.110 -.116 -.073 -.124 -.019 -.074 -.061 -.089 .018 -.037 .007 -.103 








Table 8 presents correlation analysis of inflammatory markers and neurodevelopment measures in HEU infants at 6-10 
weeks of age.  The majority of inflammatory markers GM-CSF (p0.022, r=10.309), IFN-γ (p=0.011, r=-0.339), IL-10 (p=0.001, 
r=-0.451), IL-12p70 (p=0.004, r=-0.379), IL-1β (p=0.000, r=-0.491), IL-2 (p=0.022, r=-0.308), IL-4 (p=0.002, r=-0.418), IL-6 
and Lcn2 (p=0.004, r=-0.383) were found to have a significant association with the motor neurodevelopment measure even 
after correction for multiple comparisons. MMP9 (p=0.034, r=-0.289) also did initially show to be associated with this 
measure prior to corrections. The language measure was also initially associated with MMP9 (p=0.022, r=-0.305). IL-1β 
(p=0.008, r=-0.342) further proved to be associated with the socio-emotional measure prior to corrections.  
 
Table	8:	Correlation	analysis	between	inflammatory	markers	in	HEU	infants	at	6-10	weeks	with	neurodevelopment	measures	at	24-28	months	
  GM-CSF IFN-γ IL-10 IL-12p70 IL-13 IL-1β IL-2 IL-4 IL-5 IL-6 IL-7 IL-8 TNF-α Lcn2 MMP9 
Cognitive r .005 -.178 -.136 -.089 -.091 -.207 -.126 -.164 -.010 -.181 -.238 -.225 -.178 -.153 -.186 
p-value .971 .178 .305 .501 .492 .116 .343 .214 .938 .171 .070 .086 .177 .251 .162 
Language r .081 -.106 -.116 -.055 -.025 -.199 .007 -.182 -.070 -.165 -.061 -.221 -.152 -.169 -.305* 
p-value .548 .430 .390 .684 .855 .138 .958 .177 .607 .220 .654 .098 .260 .214 .022 
Motor r -.309*# -.339*# -.451**# -.379**# -.243 -.491**# -.308*# -.418**# -.237 -.335*# -.239 -.003 -.071 -.383**# -.289* 
p-value .022 .011 .001 .004 .074 .000 .022 .002 .082 .012 .079 .981 .607 .004 .034 
Socio-emotional r -.043 -.091 -.126 -.096 -.047 -.342** -.108 -.254 -.112 .022 .003 .040 -.057 -.156 -.249 
p-value .744 .493 .342 .469 .725 .008 .415 .052 .398 .870 .984 .761 .667 .241 .060 
Adaptive Behaviour r .016 -.050 -.018 -.021 -.094 -.192 -.055 -.173 -.154 -.089 -.062 -.093 -.057 -.165 -.224 
p-value .907 .704 .891 .877 .481 .145 .680 .191 .244 .504 .643 .484 .671 .216 .091 





Table 9 presents the correlation analysis of inflammatory markers and neurodevelopment measures of HUU children at 24-
28 months. No inflammatory markers proved to have a significant association after corrections on neurodevelopment 
measures. However, it was shown that impairment in the language neurodevelopment measure was initially associated with 
GM-CSF (p=0.034, r=0.162). 
 
Table	9:	Correlation	analysis	between	inflammatory	markers	in	HUU	children	with	neurodevelopment	measures	at	24-28	months	
  GM-CSF IFN-γ IL-10 IL-12p70 IL-13 IL-1β IL-2 IL-4 IL-5 IL-6 IL-7 IL-8 TNF-α Lcn2 MMP9 
Cognitive r .034 -.100 .007 .010 -.071 -.078 -.028 .067 -.060 -.106 -.001 -.023 -.037 -.030 .034 
p-value .651 .184 .929 .892 .347 .299 .708 .376 .427 .157 .990 .759 .625 .688 .654 
Language r .162* -.061 -.001 -.006 -.101 -.057 -.017 .077 -.040 -.184* -.051 -.077 -.089 .083 .054 
p-value .034 .426 .989 .938 .191 .464 .829 .320 .601 .016 .507 .315 .248 .282 .482 
Motor r .211** -.055 .025 .067 .015 -.029 -.017 .090 .002 -.076 -.003 -.102 -.091 -.017 .002 
p-value .005 .470 .746 .378 .846 .699 .819 .235 .980 .315 .965 .179 .230 .819 .977 
Socio-emotional r .081 -.062 .041 .006 -.075 -.063 -.054 -.033 -.046 -.137 -.073 -.065 -.014 -.077 -.104 
p-value .283 .412 .589 .934 .321 .402 .472 .663 .540 .068 .332 .388 .856 .307 .166 
Adaptive Behaviour r .153* -.084 -.023 .002 -.039 -.060 -.075 .010 -.018 -.195** -.099 -.069 -.139 .020 -.071 








Table 10 presents correlation analysis of inflammatory markers and neurodevelopment measures of HEU children at 24-28 
months. No inflammatory markers were significantly associated with neurodevelopment measures after corrections for 
multiple comparisons. However, IL-10 (p=0.010, r=-0.303) did initially have an association with the cognitive 
neurodevelopment measure. The language neurodevelopment measure was also initially associated with the inflammatory 
markers IFN-γ (p=0.011, r=-0.307), IL-10 (p=0.008, r=-0.319), IL-12p70 (p=0.019, r=-0.284), IL-1β (p=0.048, r=-0.241) and IL-
2 (p=0.037, r=-0.253). 
 
Table	10:	Correlation	analysis	between	inflammatory	markers	in	HEU	children	with	neurodevelopment	measures	at	24-28	months	
  GM-CSF IFN-γ IL-10 IL-12p70 IL-13 IL-1β  IL-2 IL-4 IL-5 IL-6 IL-7 IL-8 TNF-α Lcn2 MMP9 
Cognitive r -.032 -.191 -.303* -.166 .018 -.148 -.148 -.118 .013 -.106 -.177 .010 -.054 .207 -.007 
p-value .793 .111 .010 .166 .884 .217 .219 .329 .916 .381 .139 .933 .654 .081 .956 
Language r -.234 -.307* -.319** -.284* .029 -.241* -.253* -.217 -.049 -.012 -.140 -.025 -.083 .159 -.001 
p-value .055 .011 .008 .019 .817 .048 .037 .076 .690 .922 .255 .842 .503 .193 .991 
Motor r -.050 -.073 -.215 -.143 .089 -.124 -.011 -.154 .100 .091 -.028 .105 -.027 .112 .023 
p-value .690 .562 .086 .256 .480 .326 .934 .221 .429 .473 .825 .405 .830 .371 .856 
Socio-emotional r -.011 -.060 -.042 -.093 .148 -.143 -.018 -.088 .081 .185 .018 .124 .025 .009 -.152 
p-value .929 .618 .730 .439 .218 .235 .882 .463 .505 .123 .879 .305 .836 .940 .202 
Adaptive Behaviour r -.134 -.224 -.216 -.151 .078 -.152 -.151 -.184 .082 .031 -.181 .079 -.183 .060 .008 
p-value .264 .061 .070 .209 .516 .205 .208 .125 .495 .801 .131 .515 .126 .614 .944 
p<0.05,**p<0.01
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Table 11 shows the linear regression analysis for the motor 
neurodevelopment measure with inflammatory markers for infants at 6-10 
weeks, which proved to be significant as indicated previously in Table 8. The 
inflammatory markers GM-CSF, IFN-γ, IL-10, IL-12p70, IL-1β, IL-2, IL-4, IL-6 






#covariates: Residential area, fever at time of visit, maternal smoking during pregnancy, 
maternal alcohol use during pregnancy, gestational age, maternal socioeconomic status and 





















 B (SE) β p 
GM-CSF -0.018 (0.01) -0.193 0.009 
IFN-γ -0.009 (0.01) -0.121 0.003 
IL-10 -0.11 (0.01) -0.151 0.001 
IL-12p70 -0.017 (0.01) -0.226 0.002 
IL-1β -0.014 (0.01) -0.203 0.003 
IL-2 -0.015 (0.01) -0.203 0.005 
IL-4 -0.016 (0.01) -0.164 0.031 
IL-6 -0.017 (0.01) -0.174 0.017 
Lcn2 -0.006 (0.01) -0.144 0.010 
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4. DISCUSSION 
The aim of this thesis was to delineate the relationship between the 
inflammatory environment of mothers living with HIV on antiretroviral 
therapy (ART) and their children, and the association between 
inflammatory markers and neurodevelopment in HEU children.  
 
There were three main findings. Firstly, contrary to our first hypothesis we 
found that mothers living with HIV had decreased levels of the 
inflammatory markers GM-CSF and MMP9 compared to uninfected 
mothers. Secondly, also contrary to our hypothesis, we found that the 
inflammatory markers IFN-γ and IL-1β were decreased in HEU infants at 6-
10 weeks compared to HUU infants. At 24-28 months serum levels of the 
inflammatory markers IFN-γ, IL-1β, IL-2 and IL-4 were found to be 
significantly decreased in HEU children compared with HUU children. 
Despite HEU children having reduced serum levels of inflammatory 
markers compared to HUU children the results still suggest that the 
altered inflammatory environment of the mothers living with HIV may 
predict the inflammatory environment of their children longitudinally. 
Finally, in line with our third hypothesis, we found that there was an 
association between increased inflammatory markers in HEU infants at 6-
10 weeks and impaired motor neurodevelopment at 24-28 months.  
 
The first finding that mothers living with HIV had significantly decreased 
serum levels of inflammatory markers is not consistent with the literature 
outlined in the literature review. It was expected that mothers living with 
HIV would present an elevated inflammatory environment rather than an 
inhibitory inflammatory environment. Most studies conducted so far 
indicated that three pro-inflammatory cytokines, IL-1β, IL-6 and TNF-α, 
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which play an important role in immune regulation during pregnancy, 
proved to be elevated in pregnant women living with HIV (35,41). One 
potential explanation for the findings in this study may possibly be 
explained by the subtype or clade of HIV present within our infected 
mothers. The subtypes of HIV are believed to represent different lineages 
of HIV and have been associated with different geographical regions 
(143). The mothers included in this study are of the clade C subtype. 
Clade C is the clade most prevalent within South Africa (143). Clade C 
tends to present a more immunosuppressive profile in comparison to 
other clades such as Clade B, which has shown to have a pro-
inflammatory affect and result in increased neuroinflammation due to the 
presence of the Tat protein (47,48). The Clade C subtype affects the Tat 
protein sequence; there are polymorphisms that affect specific sites on 
the Tat protein and consequently affect its biological functions. These 
polymorphisms include a serine substitution at residue 31 (C31S) and a 
serine substitution at residue 57 (R57S) (48). This therefore may explain 
the inconsistency when comparing our findings to the literature, as most 
of the literature looks at studies outside of South Africa, where the clades 
present a more inflammatory profile compared to clade C present within 
this study. It is also important to note that Clade C, in comparison to 
other clades, has been reported to have a greater association with HIV 
associated dementia (HAD) and HIV associated neurocognitive disorders 
(HAND) in South Africa (144).  
 
Furthermore, the fact that all mothers living with HIV included in this study 
were on ART may also have had an impact on the mothers’ immune 
system and resulted in the inhibitory inflammatory environment reported 
in our study. The ARVs given to the mothers living with HIV may have 
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allowed their immune system to combat the elevation in inflammatory 
markers caused by the virus resulting in the significantly decreased serum 
levels of inflammatory markers found in the mothers in this study. This 
theory is supported in a review conducted by Hileman et al, which also 
suggests that ART drastically reduces systemic inflammation and immune 
activation (145).  It may be important to note that the immune response 
can be linked to ethnicity as well as pregnancy outcome. For example, a 
study by Velez et al indicated significant differences in the cytokine levels 
between African Americans and Caucasians (146). IL-1β was shown to be 
co-regulated with several other cytokines in the amniotic fluid of African 
American women with pre-term labour, however this was not found in 
Caucasian women, indicating a difference in the underlying process 
leading to pre-term labour (146). 
 
Due to the fact that we found inflammatory markers significantly 
decreased in HEU infants and children, it is fair to suggest that the 
mothers’ inflammatory environment may have had a longitudinal 
prediction on the inflammatory environment of the children, however 
further statistical analysis is needed to confirm this. HEU infants and 
children at 6-10 weeks and 24-28 months presented significantly reduced 
serum levels of inflammatory markers, similar to that of their mothers. This 
suggests that the inhibitory immune environment in the mothers living 
with HIV may have impacted the immune environment of their children, 
which presented itself more acutely later on in life. This supports the 
concept presented by Clerici et al, which suggests that changes in the 
immune system of HEU children persist to later on in life (50). 
Additionally, studies have indicated that the first period of postnatal life 
up until 6 months is key in the programming of the immune system  
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(56,57). Furthermore, it is important to recall that a study by Kakkar et al 
reported that HEU infants might have a poorer developmental outcome 
as a result of a transferred state of immunodeficiency (55).  
 
However, it may also be possible that the significantly decreased levels of 
inflammatory markers in children at 24-28 months, is due to their immune 
system attempting to regulate itself as a result of exposure to viral 
particles. Suggesting that the inflammatory environment of the children is 
independent to that of their mothers. However, this is unlikely as the 
majority of mothers were virologically suppressed and therefor the 
exposure of the fetus in utero to viral particles would be limited. Notably, 
the mothers living with HIV had lower GM-CSF levels. GM-CSF plays an 
important function in the survival and activation of mature myeloid cells 
and contributes to the maintenance of the innate immune system (147). 
Animal studies have indicated that a reduction in GM-CSF lead to an 
impaired development of the immune system and a reduced immune 
response (148–150). It is possible; therefore, that lower GM-CSF during 
pregnancy in mothers living with HIV can contribute to the altered 
inflammatory environment in the HEU children, which is reflected by a 
reduction in inflammatory markers, IFN-γ, IL-1β, IL-2 and IL-4 in infants at 
6-10 weeks and children at 24-28 months.  
 
The decreased serum levels of inflammatory markers in the HEU infants 
and children at 6-10 weeks and 24-28 months is contrary to what is 
indicated in the majority of the literature that explores inflammatory 
markers in HEU children (21,56,74). For example, unlike in this study 
Bunders et al (62), found increased levels of IL-1β in HEU infants. 
Additionally, a study by Reikie et al (65), also reported a pro-inflammatory 
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environment in HEU children. However, there was literature that indicated 
that the immune system of HEU children did not differ to that of HUU 
children (57). Furthermore, some studies did find reduced levels of 
inflammatory markers, IL-4, IL-7 and IL-12 in HEU infants. It is also worth 
mentioning that other immunological factors, such as antibodies, cross 
the placenta during pregnancy, which may have impacted the immune 
system of the children later in life.  
 
When looking at the linear regression analysis and the relationship of the 
inflammatory markers with the neurodevelopment measures, the study 
groups were assessed individually or within-group. In the case of HEU 
infants at 6-10 weeks, we found that impaired motor neurodevelopment 
at 24-28 months was significantly associated with an increase in serum 
levels of the majority of inflammatory markers. This is most likely due to 
the fact that the immune system of the HEU infants is more sensitive and 
therefore more susceptible to changes in levels of inflammatory markers. 
The fact that the HEU infants were recently exposed to the HIV virus in 
utero explains the sensitivity of their immune system as the pathology of 
the virus is still impacting the immune system and therefore the 
neurodevelopment of these infants. This results in these infants having a 
lower threshold when it comes to dealing with fluctuations in 
inflammatory markers, unlike HUU infants. This is supported by the 
concept presented by Pollmacher et al that even low levels of cytokines 
can influence complex brain functions (84). In addition, a study conducted 
by Gilman et al, indicated that decreased serum levels of IL-8 was 
associated with higher risks of neurological abnormalities in children at 4 
years of age (151).  
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On the other hand, the immune system of HUU infants are assumed to be 
functioning under typical physiological conditions and therefore may be 
able to adapt more easily to fluctuations in inflammatory markers. 
Previous findings in animal models also suggest that maternal immune 
compromise affects neurodevelopment via changes in foetal inflammatory 
markers (28). Ultimately, this suggests that the time-point of 6-10 weeks is 
crucial to neurodevelopment, particularly motor neurodevelopment. This 
is supported by Black and Merseth (94), who highlight the importance of 
the neurodevelopmental process around the time of birth. It is important 
to mention that, although the literature is not entirely consistent; evidence 
from most recent studies relevant to HEU children did indicate impaired 
motor neurodevelopment (4).  
 
As outlined earlier in the literature review, inflammatory markers and 
cytokines can impact neurodevelopment through numerous systems, 
including glial cells, the HPA axis and neurotransmitter systems, at various 
time points in utero and in the early stages of life. The fact that HEU 
children are being exposed to HIV in utero and are subject to its 
consequences on their inflammatory environment strongly supports the 
idea that HEU children will have a sensitive immune system. This theory is 
corroborated by the review conducted by Abu-Raya et al, which 
highlights that both HIV exposure and ARV exposure impacts the immune 
system of the children (23). On the other hand, the immune system of 
HUU infants’ functions at normal physiological conditions and therefore 
can adapt much more easily to fluctuations in inflammatory markers.  
 
It is important to note that impairment in the language 
neurodevelopment measure in HEU children was also found to be initially 
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associated with increased serum levels of IFN-γ, IL-10, IL-12p70 and IL-7 
in the mothers living with HIV. However, this was not found to be 
significant after correction for multiple comparisons. Additionally, the 
same association was found in HEU children at 24-28 months, which also 
did not survive corrections for multiple comparisons. It is still important to 
mention though as many studies previously found that language was 
impacted significantly by exposure to HIV, as reported in the review 
conducted by Le Doaré et al (109). Furthermore, another recent study 
conducted on a subsample from the DCHS by Wedderburn et al (152), 
found significantly lower language scores in HEU children compared with 
HUU children, which further supports these findings.  
 
Several limitations of this study deserve emphasis. Firstly, although we 
found the inflammatory environment of the mothers to be similar to that 
of their children, the mechanism behind intergenerational transmission is 
still uncertain. Secondly, despite controlling for an array of covariates, it is 
still possible that other factors may have an influence on the 
neurodevelopment of the children. For example, many studies have 
shown that prenatal stress and mental illness in mothers may impact the 
neurodevelopment of their children (153). This was not accounted for in 
our study. Thirdly, different types of ARVs were not controlled for. As 
mentioned earlier, ARVs most likely impacted the immune system of the 
mothers resulting in an inhibitory inflammatory environment. Finally, this 
study was isolated to a specific subset of the population in South Africa, 
where all mothers in this study came from a poorer socioeconomic 
background. Low to middle income (LMIC) studies conducted has shown 
that this has an impact on the neurodevelopment of the children (154). 
Although there is evidence in this study to prove that motor and possibly 
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language neurodevelopment measures are affected, the actual 
neurobiological mechanism of these dysfunctions still remains inscrutable. 
This is due to the fact that the Bayley-III used to measure the 
neurodevelopment of the children encompasses a more general rather 
than targeted approach.  
 
Given the limitations outlined in this study, a number of future research 
directions can be suggested.  Firstly, future studies should include a more 
diverse subset of the population from different socioeconomic 
backgrounds. Secondly, controlling for different types of ARVs would also 
be beneficial to try and distinguish whether or not adaptations to the 
immune system of the mothers living with HIV and their children are due 
to infection or ARV exposure. Thirdly, in order to identify specific domain 
regions in the brain that are being impacted and causing impaired motor 
neurodevelopment, future studies should consider using a more targeted 
neuropsychological assessment. For example, one could assess magnetic 
resonance imaging (MRI) scans of infants and children to evaluate which 
particular regions of the brain are being affected. Assessments within the 
National Institutes of Health Toolbox, which includes over 100 stand-
alone measures that assess cognition, emotion, motor and sensation, 
could also be used to monitor neurodevelopment (155). Finally, although 
this study did look at two time-points in HEU children, which is quite 
extensive considering current studies conducted on HEU children, it 
would be beneficial to include more time-points. For example, the cord 
bloods of the HEU infants could be evaluated, and serums samples of the 
children at 12 months of age and then later on in life as the children 
develop through school age towards adolescence. Lastly, longitudinal 
analysis could be conducted on the serum levels of inflammatory markers 
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in order to get more clarity on whether or not the mothers’ immune 
system did indeed predict the immune system of their children.  
 
5. CONCLUSION 
This study shows that maternal HIV infection is associated with immune 
regulation, with results indicating lower serum levels of inflammatory 
markers in mothers living with HIV on ART and their HEU children. The 
results further indicated that an altered immune system in the early stages 
of life of HEU infants is associated with impaired motor 
neurodevelopment of the children later in life. The study also presented 
the likelihood that the mother’s immune system did predict that of their 
childs’ longitudinally. This highlights the need to intervene at an early 
stage in the development of HEU children to prevent neurodevelopment 
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 Mean (SD)    
 HIV- (n=190) HIV+ (n=77) t 95% CI p-value 
GM-CSF 4.0138 (0.90) 3.6475 (0.85) 3.052 .12994 .60256 .003# 
IFN-γ 2.0926 (0.68) 1.9633 (0.83) 1.315 -.06431 .32308 .190 
IL-10 2.6231 (0.97) 2.4113 (1.22) 1.493 -.06750 .49098 .137 
IL-12p70 1.3389 (0.75) 1.1674 (0.89) 1.608 -.03855 .38165 .109 
IL-13 1.8012 (1.00) 1.5341 (1.07) 1.937 -.00437 .53864 .054 
IL-1β  .4600 (0.70) .2282 (0.83) 2.316 .03473 .42891 .021 
IL-2 .8579 (0.91) .6429 (1.09) 1.653 -.04117 .47115 .100 
IL-4 3.4384 (1.01) 3.0900 (1.26) 2.370 .05894 .63777 .019 
IL-5 .9154 (0.76) .8691 (0.86) .432 -.16463 .25721 .666 
IL-6 1.0005 (0.96) .9871 (1.06) .100 -.24988 .27664 .920 
IL-7 2.4079 (0.55) 2.3732 (0.70) .431 -.12398 .19345 .667 
IL-8 1.6418 (0.93) 1.6635 (0.91) -.173 -.26804 .22465 .862 
TNF-α 1.7535 (0.54) 1.8991 (0.62) -1.923 -.29474 .00351 .056 
Lcn2 5.1494 (0.60) 5.0213 (0.61) 1.566 -.03297 .28903 .119 





 Mean (SD)     
 HUU (n=155) HEU (n=61) t 95% CI p-value 
GM CSF 2.5480 (0.98) 2.2258 (1.50) 1.865 -.01839 .66284 .064 
IFN-γ 1.6093 (0.92) 1.2071 (1.10) 2.757 .11462 .68962 .006# 
IL-10 2.5587 (0.89) 2.4162 (0.91) 1.057 -.12311 .40811 .292 
IL-12p70 0.7451 (0.92) 0.4567 (1.07) 2.000 .00424 .57254 .047 
IL-13 0.9104 (1.47) 1.0524 (1.57) -.632 -.58538 .30129 .528 
IL-1β -0.0940 (0.88) -0.4650 (0.91) 2.771 .10712 .63484 .006# 
IL-2 0.0810 (0.92) -0.1400 (1.00) 1.566 -.05721 .49921 .119 
IL-4 2.6402 (1.22) 2.2595 (1.28) 2.048 .01432 .74702 .042 
IL-5 0.2544 (0.96) 0.3970 (0.86) -1.022 -.41763 .13244 .308 
IL-6 0.6139 (1.20) 0.4270 (1.36) .994 -.18353 .55732 .321 
IL-7 1.7684 (0.72) 1.8026 (0.81) -.305 -.25545 .18706 .761 
IL-8 2.3926 (0.10) 2.3708 (1.11) .140 -.28357 .32706 .889 
TNF-α 2.9360 (0.55) 3.0252 (0.82) -.928 -.27846 .10017 .354 
Lcn2 4.6456 (0.53) 4.5154 (0.58) 1.573 -.03293 .29325 .117 






 Mean (SD)     
 HUU (n=190) HEU (n=76) t 95% CI p-value 
GM CSF 4.7496 (0.81) 4.5983 (0.95) 1.305 -.07696 .37960 .193 
IFN-γ 2.2322 (0.58) 2.0086 (0.57) 2.851 .06914 .37790 .005# 
IL-10 2.9874 (0.66) 2.8362 (0.67) 1.677 -.02630 .32879 .095 
IL-12p70 1.4775 (0.61) 1.2868 (0.64) 2.278 .02585 .35558 .024 
IL-13 2.3888 (1.07) 2.2004 (0.97) 1.336 -.08918 .46598 .183 
IL-1β  0.6314 (0.76) 0.2678 (0.67) 3.664 .16822 .55902 .000# 
IL-2 0.9467 (0.66) 0.6757 (0.73) 2.924 .08852 .45336 .004# 
IL-4 3.4085 (0.93) 3.0853 (0.99) 2.510 .06961 .57668 .013# 
IL-5 1.3115 (0.79) 1.1957 (0.70) 1.114 -.08879 .32024 .266 
IL-6 1.2464 (0.85) 1.1622 (0.90) .717 -.14731 .31587 .474 
IL-7 2.3037 (0.51) 2.2253 (0.54) 1.108 -.06084 .21756 .269 
IL-8 2.5692 (1.12) 2.4684 (1.06) .675 -.19329 .39485 .500 
TNF-α 2.5764 (0.66) 2.5338 (0.74) .460 -.13998 .22527 .646 
Lcn2 5.1152 (0.58) 5.0838 (0.57) .404 -.12152 .18431 .686 
MMP9 6.6942 (0.61) 6.6613 (0.58) .404 -.12731 .19309 .686 
 
 
